The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
Open accessAbstract
Purpose: This study compared denosumab, a fully human monoclonal anti-receptor activator of nuclear factor kappa-B ligand antibody, with zoledronic acid (ZA) for delaying or preventing skeletal-related events (SRE) in patients with advanced cancer and bone metastases (excluding breast and prostate) or myeloma. Patients and Methods: Eligible patients were randomly assigned in a double-blind, double-dummy design to receive monthly subcutaneous denosumab 120 mg (n = 886) or intravenous ZA 4 mg (dose adjusted for renal impairment; n = 890). Daily supplemental calcium and vitamin D were strongly recommended. The primary end point was time to first on-study SRE (pathologic fracture, radiation or surgery to bone, or spinal cord compression). Results: Denosumab was noninferior to ZA in delaying time to first on-study SRE (hazard ratio, 0.84; 95% CI, 0.71 to 0.98; P = .0007). Although directionally favorable, denosumab was not statistically superior to ZA in delaying time to first on-study SRE (P = .03 unadjusted; P = .06 adjusted for multiplicity) or time to first-and-subsequent (multiple) SRE (rate ratio, 0.90; 95% CI, 0.77 to 1.04; P = .14). Overall survival and disease progression were similar between groups. Hypocalcemia occurred more frequently with denosumab. Osteonecrosis of the jaw occurred at similarly low rates in both groups. Acute-phase reactions after the first dose occurred more frequently with ZA, as did renal adverse events and elevations in serum creatinine based on National Cancer Institute Common Toxicity Criteria for Adverse Events grading. Conclusion: Denosumab was noninferior (trending to superiority) to ZA in preventing or delaying first on-study SRE in patients with advanced cancer metastatic to bone or myeloma. Denosumab represents a potential novel treatment option with the convenience of subcutaneous administration and no requirement for renal monitoring or dose adjustment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,755
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
Coleman, R. E. (2001) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0210 · Cited by 1,920
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,656
Denosumab in postmenopausal women with low bone mineral density.
McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228
Hortobagyi, G. N., Theriault, R. L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J., Knight, R. D., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612123352401 · Cited by 1,026
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A. R., Mackey, J. R., Apffelstaedt, J., Hussein, M., Coleman, R. E., Reitsma, D. J., et al. (2001) · PubMed · Cited by 896
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M. A., Coleman, R. E., Reitsma, D. J., et al. (2003) · Cancer · doi:10.1002/cncr.11701 · Cited by 873
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Rosen, L. S., Gordon, D., Tchekmedyian, N. S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., Zheng, M., Urbanowitz, G., et al. (2004) · Cancer · doi:10.1002/cncr.20308 · Cited by 705
Self-citationBerenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.593 · Cited by 648
Brown, J. E., Cook, R. J., Major, P., Lipton, A., Saad, F., Smith, M., Lee, K.-A., Zheng, M., Hei, Y.-J., & Coleman, R. E. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji002 · Cited by 559
Fizazi, K., Lipton, A., Mariette, X., Body, J.-J., Rahim, Y., Gralow, J. R., Gao, G., Wu, L., Sohn, W., & Jun, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2146 · Cited by 533
Self-citationColeman, R. E., Major, P., Lipton, A., Brown, J. E., Lee, K.-A., Smith, M., Saad, F., Zheng, M., Hei, Y. J., Seaman, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.091 · Cited by 533
Body, J.-J., Facon, T., Coleman, R. E., Lipton, A., Geurs, F., Fan, M., Holloway, D., Peterson, M. C., & Bekker, P. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1933 · Cited by 490
Elimination mechanisms of therapeutic monoclonal antibodies
Tabrizi, M. A., Tseng, C.-M. L., & Roskos, L. K. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03638-x · Cited by 478
Launay‐Vacher, V., Oudard, S., Janus, N., Gligorov, J., Pourrat, X., Rixe, O., Morere, J., Beuzeboc, P., Deray, G., & On behalf of the Renal Insufficiency and Cancer Medications (IRMA) Study Group (2007) · Cancer · doi:10.1002/cncr.22904 · Cited by 458
Aapro, M., Abrahamsson, P. A., Body, J. J., Coleman, R. E., Colomer, R., Costa, L., Crinò, L., Dirix, L., Gnant, M., Gralow, J., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm442 · Cited by 457
Self-citationNCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
Lipton, A., Steger, G. G., Figueroa, J., Alvarado, C., Solal-Celigny, P., Body, J.-J., de Boer, R., Berardi, R., Gascon, P., Tonkin, K. S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8604 · Cited by 389
Self-citationBisphosphonates: Clinical Experience
Coleman, R. E. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90004-14 · Cited by 384
Weinfurt, K. P., Li, Y., Castel, L. D., Saad, F., Timbie, J. W., Glendenning, G. A., & Schulman, K. A. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi122 · Cited by 362
Management of bone metastases in cancer: A review
Selvaggi, G., & Scagliotti, G. V. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.03.011 · Cited by 266
Self-citationChristodoulou, C., Pervena, A., Klouvas, G., Galani, E., Falagas, M. E., Tsakalos, G., Visvikis, A., Nikolakopoulou, A., Acholos, V., Karapanagiotidis, G., et al. (2009) · Oncology · doi:10.1159/000201931 · Cited by 232
Hofbauer, L. C., Neubauer, A., & Heufelder, A. E. (2001) · Cancer · doi:10.1002/1097-0142(20010801)92:3<460::aid-cncr1344>3.0.co;2-d · Cited by 215
Some fundamental issues with non‐inferiority testing in active controlled trials
James Hung, H. M., Wang, S., Tsong, Y., Lawrence, J., & O'Neil, R. T. (2003) · Statistics in Medicine · doi:10.1002/sim.1315 · Cited by 205
Aragon‐Ching, J. B., Ning, Y. M., Chen, C. C., Latham, L. L., Guadagnini, J.-P., Gulley, J. L., Arlen, P. M., Wright, J. J., Parnes, H. L., Figg, W. D., et al. (2009) · Cancer Investigation · doi:10.1080/07357900802208608 · Cited by 134
Cimino, M. A., Rotstein, C., Slaughter, R. L., & Emrich, L. J. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90947-8 · Cited by 128
Vogel, C. L., Yanagihara, R. H., Wood, A. J., Schnell, F. M., Henderson, C., Kaplan, B. H., Purdy, M. H., Orlowski, R., Decker, J. L., Lacerna, L. V., et al. (2004) · The Oncologist · doi:10.1634/theoncologist.9-6-687 · Cited by 76
Treatment for Myeloma Bone Disease
Yeh, H., & Berenson, J. R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0681 · Cited by 46
Self-citationNCCN Task Force Report: Bone Health and Cancer Care
Theriault, R. L., Biermann, J. S., Brown, E., Brufsky, A., Demers, L. M., Grewal, R. K., Guise, T. A., Jackson, R. D., McEnery, K. W., Podoloff, D. A., et al. (2006) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2006.2002 · Cited by 30
Cited by
Ruggiero, S. L., Dodson, T. B., Fantasia, J., Goodday, R., Aghaloo, T., Mehrotra, B., & O'Ryan, F. (2014) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2014.04.031 · Cited by 2,905
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
“Denosumab shows a trend towards superiority to zoledronic acid in lung cancer in terms of SRE prevention [II, B] [317].”
BackgroundRenal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Escudier, B., Porta, C., Schmidinger, M., Algaba, F., Patard, J. J., Khoo, V., Eisen, T., & Horwich, A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu259 · Cited by 2,251
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Self-citation
Metadata
- Authors
- Henry, D. H., Costa, L., Goldwasser, F., Hirsh, V., Hungria, V., Prausova, J., Scagliotti, G. V., Sleeboom, H., Spencer, A., Vadhan-Raj, S., von Moos, R., Willenbacher, W., Woll, P. J., Wang, J., Jiang, Q., Jun, S., Dansey, R., & Yeh, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-03-20
- Volume
- 29
- Issue
- 9
- Pages
- 1125-1132
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2149775776
- Cited by
- 1,263
- References
- 32
- FWCI
- 59.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.